This activity will discuss how primary clinicians can address barriers to early initiation and appropriate intensification of insulin in patients with T2DM; recommend appropriate basal insulin regimens based on patients’ clinical needs, hypoglycemia risk, and drug clinical profile; and be aware of new and emerging basal insulins, which may have the potential of improving T2DM treatment and patient outcomes.
Diabetes continues to have a significant impact on morbidity and mortality in the United States, and is an ongoing treatment challenge for primary care providers who lack confidence with treatment intensification including newer agents and combination therapies resulting in clinical inertia. Further, approaches to improved adherence and lifestyle modification through shared-decision making continue to evolve with the goal of improving quality of care.
The expanded number of therapies with varying mechanisms of action for type 2 diabetes has resulted in novel combination regimens for patients not achieving goals despite therapy with metformin. Dr. Serge Jabbour will review novel combinations and approaches to intensifying therapy in this interactive case study.
Depending on whether you count all insulins as one or count them as multiple classes, there are now between 13 and 19 classes of antihyperglycemic agents that have been approved by the US FDA for the treatment of people with type 2 diabetes mellitus (T2DM). Insulin remains the most effective antihyperglycemic agent, and many, if not most, patients with T2DM will eventually require treatment with one or more of the increasing insulin therapy options. In this case compendium, Lawrence Blonde, MD, discusses patients at different stages of T2DM to illustrate how clinicians can better utilize insulin therapy options to attain glycemic control and improve the overall health outcomes of patients with T2DM